Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 3Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1045Lung Neoplasms 803Small Cell Lung Carcinoma 193Breast Neoplasms 158Colorectal Neoplasms 157Neoplasms 128Melanoma 116Ovarian Neoplasms 111Pancreatic Neoplasms 107Stomach Neoplasms 95Neoplasm Metastasis 89Esophageal Neoplasms 77Squamous Cell Carcinoma of Head and Neck 75Prostatic Neoplasms 66Uterine Cervical Neoplasms 65Head and Neck Neoplasms 65Endometrial Neoplasms 61Triple Negative Breast Neoplasms 59Colonic Neoplasms 58Carcinoma, Renal Cell 58Mesothelioma, Malignant 48Adenocarcinoma of Lung 48Urinary Bladder Neoplasms 47Carcinoma, Hepatocellular 46Mesothelioma 42Sarcoma 40Brain Neoplasms 40Liver Neoplasms 38Disease 34NSCLC 33

Interventions

pembrolizumab 1osimertinib 1cemiplimab 1Vascular Endothelial Growth Factor A 1Paroxetine 1Paclitaxel 1Itraconazole 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Lethal Congenital Contracture Syndrome 2 × Thoracic × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

NCT07111520 2026-05-05

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

BioNTech SE

Phase 1/2 Recruiting
420 enrolled
Thoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung

NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡